Showing results for 
Search instead for 
Did you mean: 

Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.

Reputable Mentor II
Reputable Mentor II
Zhang X, Hernandez I, Rei D, Mair W, Laha JK, Cornwell ME, Cuny GD, Tsai LH, Steen JA, Kosik KS.
J Biol Chem. 2013 Jul 26;288(30):22042-56. doi: 10.1074/jbc.M112.436402. Epub 2013 Jun 4.
Although Tau accumulation is a feature of several neurodegenerative conditions, treatment options for these conditions are nonexistent. Targeting Tau kinases represents a potential therapeutic approach. Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β. Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range. Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25. Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404. Treatment also induced the recovery of memory in a fear conditioning assay. Given the contribution of both CDK5/p25 and GSK3β to Tau phosphorylation, effective treatment of tauopathies may require dual kinase targeting.
University of California at Santa Barbara
Version history
Last update:
‎10-15-2021 05:52 AM
Updated by: